Knowing how to preserve human embryonic stem cells in their pluripotent state until they are needed will help scientists better harness these cells for use in a variety of therapies. Now researchers have identified a gene receptor and signaling pathway that plays an essential role in preserving hESCs in an undifferentiated state.
International Stem Cell Corp. has found a new way to genetically reprogram mature cells into an embryonic-like state, a technique the Carlsbad, CA-based company believes is a safer and more efficient way of creating induced pluripotent stem cells.
Using stem cell technology, Johns Hopkins researchers and collaborators at Isis Pharmaceuticals have developed several new compounds that seem to halt the toxic effects that lead to brain destruction in amyotrophic lateral sclerosis and dementia in lab studies.
Using cell material from mice, an international team led by researchers at the University of Copenhagen's Danish Stem Cell Center has developed a way to grow a miniature 3-D pancreas.
Combining gene therapy plus an infusion of stem cells helps heal wounds faster in mice, a discovery that could eventually lead to better treatments for older people with wounds, who fail to heal as well as younger patients.
The outlook for young patients diagnosed with medulloblastoma is grim. The highly malignant brain tumor mostly affects children, and treatments are aggressive, often leaving patients with severe side effects, such as lowered IQ levels and increased susceptibility to other cancers.
Embryonic stem cells have huge potential for treating disease because of their ability to differentiate into virtually any kind of human cell. The process of creating such cells has been slow, and embryonic stem cell-based therapies are not yet ready for medical use.
A cellular therapy developed by Newark, NJ-based StemCells preserved sight in a rat model of retinal disease, pointing to a promising new option to treat vision loss.
In rats with tendon injuries that were treated with Pluristem Therapeutics' PLacental eXpanded (PLX) stem cell therapy, animals showed tendon healing at two and four weeks following injection, compared to saline-treated rats, according to the Haifa, Israel-based company.
A new stem cell treatment that combines neural stem cells with chemo-radiotherapy drugs could provide a better way to combat glioblastoma, the most common and lethal form of adult brain cancer.